Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Abbreviations
artemether + lumefantrine
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04300309 CALINA (CCOA566B2307)
Malaria, uncomplicated (<5kg patients)
Phase 3
Artemether Cmax
Target Patients
Read-out Milestone(s)
Publication
Experimental: artemether lumefantrine (2.5 mg:30 mg)
artemether lumefantrine (2.5 mg:30 mg) bid over 3 days, from 1-4 tablets per dose
Infants and Neonates <5 kg body weight with acute uncomplicated plasmodium
falciparum malaria
Primary outcome measure: 2023
TBD
144 Investor Relations | Q4 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation